B-
BiotechTV - News
Jefferies London 2026: Valneva CEO Thomas Lingelbach shares an update on the status of the company's Lyme disease program (partnered with Pfizer) and more pipeline projects
0:00-12:37
He discusses the regulatory status of Lyme disease, which hit on secondary enpoints in its phase three trial but narrowly missed the primary. Plus, updates on chikungunya and shigella.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/Jefferies-London-2026-Valneva-CEO-Thomas-Lingelbach-shares-an-update-on-the-status-of-the-companys-Lyme-disease-program-partnered-with-Pfizer-and-more-pipeline-projects-e3shjsn
Published
November 17, 2026
Duration
13 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#valnevaceothomas #companyslymedisease #pipelineprojects #lifesciences
